DK0640131T3 - Gensplejsere antistoffer - Google Patents

Gensplejsere antistoffer

Info

Publication number
DK0640131T3
DK0640131T3 DK93905306T DK93905306T DK0640131T3 DK 0640131 T3 DK0640131 T3 DK 0640131T3 DK 93905306 T DK93905306 T DK 93905306T DK 93905306 T DK93905306 T DK 93905306T DK 0640131 T3 DK0640131 T3 DK 0640131T3
Authority
DK
Denmark
Prior art keywords
pct
antibodies
date sep
sec
melanoma
Prior art date
Application number
DK93905306T
Other languages
Danish (da)
English (en)
Inventor
Norman Hardman
Gerd Pluschke
Brendan Murray
Original Assignee
Novartis Ag
Novartis Erfind Verwalt Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Erfind Verwalt Gmbh filed Critical Novartis Ag
Application granted granted Critical
Publication of DK0640131T3 publication Critical patent/DK0640131T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
    • F02B75/00—Other engines
    • F02B75/02—Engines characterised by their cycles, e.g. six-stroke
    • F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
    • F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
DK93905306T 1992-03-17 1993-03-05 Gensplejsere antistoffer DK0640131T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92810188 1992-03-17
PCT/EP1993/000505 WO1993019180A1 (en) 1992-03-17 1993-03-05 Genetically engineered antibodies

Publications (1)

Publication Number Publication Date
DK0640131T3 true DK0640131T3 (da) 1999-11-01

Family

ID=8211884

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93905306T DK0640131T3 (da) 1992-03-17 1993-03-05 Gensplejsere antistoffer

Country Status (12)

Country Link
US (1) US5866124A (es)
EP (1) EP0640131B1 (es)
JP (1) JPH07504802A (es)
AT (1) ATE179210T1 (es)
AU (1) AU673347B2 (es)
CA (1) CA2130173A1 (es)
DE (1) DE69324579T2 (es)
DK (1) DK0640131T3 (es)
ES (1) ES2131107T3 (es)
GR (1) GR3030702T3 (es)
MX (1) MX9301500A (es)
WO (1) WO1993019180A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018540A1 (en) * 1991-04-18 1992-10-29 Mount Sinai School Of Medicine Of The City University Of New York Anti-human immunodeficiency virus recombinant antibodies
EP0674907A3 (en) * 1994-03-21 1996-03-13 Ciba Geigy Ag Antibody-carrier protein conjugates, for use in active immunotherapy.
DE19911329A1 (de) * 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7468254B2 (en) * 2003-01-21 2008-12-23 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
UY28886A1 (es) * 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
MX2007011407A (es) * 2005-03-25 2007-11-13 Glycart Biotechnology Ag Moleculas de union a antigeno dirigidas a proteoglicano de condroitinsulfato de melanoma y con aumento de afinidad de union al receptor fc y de funcion efectora.
RU2006112025A (ru) * 2005-12-16 2007-10-27 Хелт Рисерч Инк. (Us) Пептиды для стимуляции иммунного ответа против меланомы
CA2737597C (en) 2008-10-16 2017-03-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
CN108892726A (zh) 2011-06-13 2018-11-27 艾比吉诺米克斯合作公司 抗psgl-1抗体及其用途
US9783613B2 (en) 2011-10-04 2017-10-10 Igem Therapeutics Limited IgE anti-HMW-MAA antibody
MX2017003247A (es) 2014-09-15 2017-11-30 Amgen Inc Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
EP3774881A1 (en) 2018-04-02 2021-02-17 Amgen Inc. Erenumab compositions and uses thereof
CN115349490B (zh) * 2022-07-14 2024-01-12 成都中医药大学 一种卵巢储备功能低下动物模型的建立方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0141783B2 (en) * 1983-11-07 1993-06-16 The Wistar Institute Immune response to tumours and viruses induced by anti-idiotype antibodies
US4918164A (en) * 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
DE68920016T2 (de) * 1988-05-17 1995-04-20 Soldano Ferrone Anti-idiotyp-antikörper gegen antimenschliche hochmolekulare, an melanomen assoziierte antigene.
CA2065414C (en) * 1989-09-15 2007-05-15 Tse-Wen Chang Treatment of autoimmune disease
DE69024758T2 (de) * 1989-11-14 1996-08-29 New York Medical College Neuartige antiidiotypische monoklonale Antikörper

Also Published As

Publication number Publication date
JPH07504802A (ja) 1995-06-01
ATE179210T1 (de) 1999-05-15
GR3030702T3 (en) 1999-11-30
EP0640131B1 (en) 1999-04-21
DE69324579T2 (de) 1999-09-23
DE69324579D1 (de) 1999-05-27
ES2131107T3 (es) 1999-07-16
WO1993019180A1 (en) 1993-09-30
US5866124A (en) 1999-02-02
CA2130173A1 (en) 1993-09-30
EP0640131A1 (en) 1995-03-01
AU673347B2 (en) 1996-11-07
AU3631393A (en) 1993-10-21
MX9301500A (es) 1993-12-01

Similar Documents

Publication Publication Date Title
DK0640131T3 (da) Gensplejsere antistoffer
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
ATE197592T1 (de) Monoklonaler antikörper gegen cd44v6
EP0671920A4 (en) AN ANTI-IDIOTYPICAL ANTIBODY AND ITS USE IN THE DIAGNOSIS AND THERAPY OF HIV-RELATED DISEASES.
ATE240395T1 (de) Antikörper gegen e-selektin
DE69738984D1 (de) Mutierte nicht aktivierende igg2 domäne und diese sequenz enthaltende anti-cd3 antikörper
DE69129302D1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
ATE207080T1 (de) Multivalente antigen-bindende proteine
PT741716E (pt) Analogos de delta 12,13-iso-taxol sua utilizacao anti-neoplasica e composicoes farmaceuticas que os contem
ATE480566T1 (de) Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
FI972703A (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
ATE244299T1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
DK0845998T3 (da) Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles
ATE258057T1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
DK0600396T3 (da) Vacciner mod tarmprotozoer
DE69721485D1 (de) Durch hla-b44 moleküle präsentierte tumor-abstossungsantigene und ihre verwendungen
DK0649433T3 (da) Antigeniske regioner fra komplekser af tumorfrigivne partikler (TLP) og antistoffer mod sådanne.
DK1039931T3 (da) Multivalente rekombinante antistoffer til at behandle HRV infektioner
DE59006159D1 (de) Verwendung von macrolactonen als antiallergica.
GB9715177D0 (en) Medicament
AU3283693A (en) Specific antibodies against activated platelets, the preparation thereof and the use thereof in diagnosis and therapy